|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.25 GBX | -8.16% |
|
0.00% | -4.26% |
| 06-10 | Ixico cheers FDA approval for contractor Fujirebio's Alzheimer's test | AN |
| 06-10 | IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic Biomarker | CI |
| Capitalization | 10.43M 14.12M 12.25M 11.46M 19.2M 1.22B 21.75M 134M 52.37M 557M 53M 51.9M 2.04B | P/E ratio 2025 * |
-5.36x | P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 7.53M 10.2M 8.84M 8.28M 13.86M 878M 15.7M 96.87M 37.81M 402M 38.26M 37.46M 1.47B | EV / Sales 2025 * |
1.24x | EV / Sales 2026 * | - |
| Free-Float |
69.39% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: IXICO plc
More press releases
| 1 day | -8.16% | ||
| 1 month | +21.62% | ||
| 3 months | +20.00% | ||
| 6 months | -2.17% | ||
| Current year | -4.26% |
| 1 week | 10.66 |  | 15 |
| 1 month | 8.5 | | 15 |
| Current year | 7.35 | | 15 |
| 1 year | 6.45 | | 15 |
| 3 years | 6.35 | | 43 |
| 5 years | 6.35 | | 127 |
| 10 years | 6.35 | | 127 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 51 | 2024-08-18 |
Grant Nash
DFI | Director of Finance/CFO | 48 | 2019-08-20 |
Romina Oxborough
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 50 | - |
Grant Nash
BRD | Director/Board Member | 48 | 2019-08-20 |
| Director/Board Member | 58 | 2022-01-20 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -8.16% | 0.00% | +63.64% | -70.00% | 14.17M | ||
| -2.50% | -0.80% | +18.43% | +13.26% | 49.5B | ||
| -1.41% | +3.00% | -26.26% | -21.90% | 27.14B | ||
| -1.89% | +2.53% | -4.26% | +17.06% | 26.06B | ||
| -0.17% | +3.36% | +15.73% | -22.51% | 12.53B | ||
| +0.07% | +14.84% | +77.09% | - | 12.34B | ||
| -0.97% | +4.71% | -53.51% | -28.71% | 11.57B | ||
| -2.49% | -2.88% | -80.95% | -78.06% | 10.31B | ||
| -0.07% | -1.31% | +33.81% | +110.24% | 10.31B | ||
| -0.59% | +3.58% | +8.18% | +3.37% | 10.2B | ||
| Average | -1.82% | +2.49% | +5.19% | -8.58% | 17B | |
| Weighted average by Cap. | -1.51% | +1.91% | +1.27% | +1.63% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.05M 8.2M 7.11M 6.65M 11.14M 706M 12.62M 77.88M 30.39M 323M 30.76M 30.12M 1.18B | - |
| Net income | -1.78M -2.42M -2.09M -1.96M -3.28M -208M -3.72M -22.95M -8.96M -95.27M -9.06M -8.88M -349M | - |
| Net Debt | -2.9M -3.93M -3.41M -3.19M -5.34M -338M -6.05M -37.33M -14.57M -155M -14.74M -14.44M -567M | - |
More financial data
* Estimated data
Employees
81
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-13 | 11.25 p | -8.16% | 74,885 |
| 25-06-12 | 12.25 p | -5.77% | 175,117 |
| 25-06-11 | 13.00 p | +1.96% | 247,753 |
| 25-06-10 | 12.75 p | +10.87% | 663,405 |
| 25-06-09 | 11.50 p | +2.22% | 344,158 |
Delayed Quote London S.E., June 13, 2025 at 11:35 am
More quotes
Annual profits - Rate of surprise
- Stock Market
- Equities
- IXI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition